Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer

被引:28
|
作者
Hondelink, Liesbeth M. [1 ]
Huyuk, Melek [2 ]
Postmus, Pieter E. [2 ]
Smit, Vincent T. H. B. M. [1 ]
Blom, Sami [3 ]
von der Thusen, Jan H. [4 ]
Cohen, Danielle [1 ]
机构
[1] Leiden Univ, Dept Pathol, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands
[3] Aiforia Technol Oy, Helsinki, Finland
[4] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
关键词
artificial intelligence; computational pathology; immunotherapy; non-small cell lung cancer; programmed death-ligand 1; PD-L1; IMMUNOHISTOCHEMISTRY; PEMBROLIZUMAB;
D O I
10.1111/his.14571
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) has several drawbacks: a robust gold standard is lacking, and there is substantial interobserver and intraobserver variance, with up to 20% discordance around cutoff points. The aim of this study was to develop a new deep learning-based PD-L1 tumour proportion score (TPS) algorithm, trained and validated on a routine diagnostic dataset of digitised PD-L1 (22C3, laboratory-developed test)-stained samples. Methods and results We designed a fully supervised deep learning algorithm for whole-slide PD-L1 assessment, consisting of four sequential convolutional neural networks (CNNs), using aiforia create software. We included 199 whole slide images (WSIs) of 'routine diagnostic' histology samples from stage IV NSCLC patients, and trained the algorithm by using a training set of 60 representative cases. We validated the algorithm by comparing the algorithm TPS with the reference score in a held-out validation set. The algorithm had similar concordance with the reference score (79%) as the pathologists had with one another (75%). The intraclass coefficient was 0.96 and Cohen's kappa coefficient was 0.69 for the algorithm. Around the 1% and 50% cutoff points, concordance was also similar between pathologists and the algorithm. Conclusions We designed a new, deep learning-based PD-L1 TPS algorithm that is similarly able to assess PD-L1 expression in daily routine diagnostic cases as pathologists. Successful validation on routine diagnostic WSIs and detailed visual feedback show that this algorithm meets the requirements for functioning as a 'scoring assistant'.
引用
收藏
页码:635 / 647
页数:13
相关论文
共 50 条
  • [31] Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
    Ricci, Costantino
    Capizzi, Elisa
    Giunchi, Francesca
    Casolari, Laura
    Gelsomino, Francesco
    Rihawi, Karim
    Natali, Filippo
    Livi, Vanina
    Trisolini, Rocco
    Fiorentino, Michelangelo
    Ardizzoni, Andrea
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [32] Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
    Sahin, Songul
    Batur, Sebnem
    Aydin, Ovgu
    Ozturk, Tulin
    Turna, Akif
    Oz, Buge
    BALKAN MEDICAL JOURNAL, 2019, 36 (03) : 184 - 189
  • [33] Immunohistochemical (IHC) scoring of programmed death-ligand 1 (PD-L1) protein expression in non-small cell lung cancer (NSCLC) using an automated digital pathology algorithm
    Miri, M. S.
    Marati, V.
    Inge, L.
    Jimenez, J.
    Chen, C.
    Zuiderveld, K.
    Hayden, D.
    Lopez, B.
    Luu, D.
    Ranger-Moore, J.
    Guetter, C.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S132 - S132
  • [34] Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response
    Choi, Sangjoon
    Cho, Soo Ick
    Ma, Minuk
    Park, Seonwook
    Pereira, Sergio
    Aum, Brian Jaehong
    Shin, Seunghwan
    Paeng, Kyunghyun
    Yoo, Donggeun
    Jung, Wonkyung
    Ock, Chan-Young
    Lee, Se-Hoon
    Choi, Yoon-La
    Chung, Jin-Haeng
    Mok, Tony S.
    Kim, Hyojin
    Kim, Seokhwi
    EUROPEAN JOURNAL OF CANCER, 2022, 170 : 17 - 26
  • [35] Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images
    van Eekelen, Leander
    Spronck, Joey
    Looijen-Salamon, Monika
    Vos, Shoko
    Munari, Enrico
    Girolami, Ilaria
    Eccher, Albino
    Acs, Balazs
    Boyaci, Ceren
    de Souza, Gabriel Silva
    Demirel-Andishmand, Muradije
    Meesters, Luca Dulce
    Zegers, Daan
    van der Woude, Lieke
    Theelen, Willemijn
    van den Heuvel, Michel
    Gruenberg, Katrien
    van Ginneken, Bram
    van der Laak, Jeroen
    Ciompi, Francesco
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [36] Best regimens for treating chemo-naive incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis
    Fukuda, Nobuhiko
    Horita, Nobuyuki
    Katakura, Seigo
    Namkoong, Ho
    Kaneko, Ayami
    Somekawa, Kouhei
    Tagami, Youichi
    Watanabe, Keisuke
    Hara, Yu
    Kobayashi, Nobuaki
    Kaneko, Takeshi
    THORACIC CANCER, 2022, 13 (01) : 84 - 94
  • [37] Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer
    Nagasaki, Yusuke
    Taki, Tetsuro
    Nomura, Kotaro
    Tane, Kenta
    Miyoshi, Tomohiro
    Samejima, Joji
    Aokage, Keiju
    Ohtani-Kim, Seiyu Jeong-Yoo
    Kojima, Motohiro
    Sakashita, Shingo
    Sakamoto, Naoya
    Ishikawa, Shumpei
    Suzuki, Kenji
    Tsuboi, Masahiro
    Ishii, Genichiro
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (07): : 1158 - 1168
  • [38] The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
    Ma, Guangzhi
    Deng, Yunfu
    Jiang, Hai
    Li, Wen
    Wu, Qiang
    Zhou, Qinghua
    CLINICA CHIMICA ACTA, 2018, 482 : 101 - 107
  • [39] Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
    Garg, Gaurav
    Prasad, Kuruswamy Thurai
    Singh, Navneet
    Gupta, Parul
    Muthu, Valliappan
    Das, Ashim
    Bal, Amanjit
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2021, 55 (06) : 398 - 405
  • [40] Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
    Liam, Chong Kin
    Yew, Chian Yih
    Pang, Yong Kek
    Wong, Chee Kuan
    Poh, Mau Ern
    Tan, Jiunn Liang
    Soo, Chun Ian
    Loh, Thian Chee
    Chin, Ka Kiat
    Munusamy, Vijayan
    Liam, Yong Sheng
    Ibrahim, Nur Husna
    BMC CANCER, 2023, 23 (01)